AP 1101Alternative Names: AP-1101
Latest Information Update: 05 Aug 2015
At a glance
- Originator Ariel Pharmaceuticals
- Class Cytoprotectives; Neuroprotectants; Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cognition disorders; Memory disorders
Most Recent Events
- 23 Sep 2011 Phase-II clinical trials in Neuroprotection/Cognition disorders (prevention) in USA (IV)